Form 13-F position report

GINKGO BIOWORKS HOLDINGS INC C

Reported by GEODE CAPITAL MANAGEMENT LLC

DNA CUSIP 37611X100 Manager CIK 0001214717

Reported 12,020,740 shares, up 2,220,836 (22.7%) from the prior quarter.

Reported value -27.6%; share count 22.7% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 12,020,740 Quarter-end amount reported
Reported value $28,609,000 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 81143000
2022-03-31 39493000
2022-06-30 28609000
2022-09-30 31418000
2022-12-31 19899000
2023-03-31 18202916
2023-06-30 32233218
2023-09-30 36276193
2023-12-31 35644085
2024-03-31 25397958
2024-06-30 5121133
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for GINKGO BIOWORKS HOLDINGS INC C held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -15,312,270 (-100.0%) 0 $0 2024-11-12
Q2 2024 Reduced 15,312,270 -6,578,295 (-30.1%) < 0.01% $5,121,133 2024-08-09
Q1 2024 Added 21,890,565 +802,714 (3.8%) < 0.01% $25,397,958 2024-05-13
Q4 2023 Added 21,087,851 +1,049,210 (5.2%) < 0.01% $35,644,085 2024-02-13
Q3 2023 Added 20,038,641 +2,708,961 (15.6%) < 0.01% $36,276,193 2023-11-13
Q2 2023 Added 17,329,680 +3,643,284 (26.6%) < 0.01% $32,233,218 2023-08-11
Q1 2023 Added 13,686,396 +1,911,342 (16.2%) < 0.01% $18,202,916 2023-05-15
Q4 2022 Added 11,775,054 +1,704,984 (16.9%) < 0.01% $19,899,000 2023-02-13
Q3 2022 Reduced 10,070,070 -1,950,670 (-16.2%) < 0.01% $31,418,000 2022-11-14
Q2 2022 Added 12,020,740 +2,220,836 (22.7%) < 0.01% $28,609,000 2022-08-12
Q1 2022 Added 9,799,904 +35,401 (0.4%) < 0.01% $39,493,000 2022-05-13
Q4 2021 New 9,764,503 +9,764,503 (0.0%) < 0.01% $81,143,000 2022-02-11

Who else reported the position

278 managers reported GINKGO BIOWORKS HOLDINGS INC C for Q2 2022.

Managers reporting GINKGO BIOWORKS HOLDINGS INC C in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BAILLIE GIFFORD & CO Added 205,327,786 +37,575,106 0.5% $488,680,000 4 qtrs
ARK Investment Management LLC Added 87,358,057 +22,824,417 1.59% $269,063,000 4 qtrs
VANGUARD GROUP INC Added 86,735,032 +57,401,650 < 0.01% $206,429,000 3 qtrs
GENERAL ATLANTIC L P Reduced 69,435,733 -21,375,081 2.16% $165,257,000 4 qtrs
Anchorage Capital Group L L C Unchanged 69,158,354 0 16.46% $164,597,000 4 qtrs
MORGAN STANLEY Added 39,213,029 +14,233,562 0.01% $93,329,000 4 qtrs
BlackRock Inc Added 32,353,263 +16,399,997 < 0.01% $77,001,000 3 qtrs
VIKING GLOBAL INVESTORS LP Reduced 27,084,126 -23,971,018 0.29% $64,460,000 4 qtrs
Nikko Asset Management Americas Inc Added 21,858,173 +6,937,185 0.65% $52,678,000 4 qtrs
Sumitomo Mitsui Trust Holdings Inc New 21,858,173 +21,858,173 0.04% $52,022,000 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 12, 2022
Filing type
13F-HR
Position type
CL A SHS

Voting authority reported

Sole
12,020,740
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.